A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

NCT00569140 ·Status: COMPLETED ·Phase: PHASE1

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128 ·Status: COMPLETED ·Phase: PHASE1

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

NCT03335852 ·Status: COMPLETED ·Phase: PHASE1

Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD

NCT00509548 ·Status: TERMINATED ·Phase: PHASE2

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

NCT00446654 ·Status: COMPLETED ·Phase: PHASE1

A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

NCT01013376 ·Status: COMPLETED ·Phase: PHASE1

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

NCT01003691 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

NCT00782093 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

NCT04270669 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

NCT05953012 ·Status: COMPLETED ·Phase: PHASE1

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

NCT00150202 ·Status: COMPLETED ·Phase: PHASE3

Ocular Safety and Usability Study for FYB201 PFS

NCT06708624 ·Status: COMPLETED ·Phase: PHASE4

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

NCT01089517 ·Status: COMPLETED ·Phase: PHASE2

Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

NCT03777254 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

NCT05904691 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

NCT00877032 ·Status: COMPLETED ·Phase: PHASE1

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

NCT01505062 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

NCT00447980 ·Status: COMPLETED ·Phase: PHASE2

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

NCT03846193 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

NCT05161806 ·Status: COMPLETED ·Phase: PHASE3

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

NCT06952842 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

NCT05282004 ·Status: COMPLETED ·Phase: PHASE3

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

NCT00541333 ·Status: SUSPENDED ·Phase: PHASE1